Our world-class research infrastructure offers accessible and streamlined access to over 460,000 cancer biospecimens and a rich repository of associated clinical data. We also offer bespoke prospective collections and specimen services for clinical trials.
This invaluable biobanking infrastructure is made possible through the joint effort of the VCB consortium, as well as donations from almost 40,000 Victorians. Their generosity has supported over 300 academic and commercial research projects, resulting in over 300 highly impactful scientific publications and a number of successful commercialisations.
Connecting the expertise of major tissue banks across Melbourne
Led by Cancer Council Victoria, the VCB consortium is comprised of five leading health agencies including Austin Health, Eastern Health, Melbourne Health, Monash Health and Peter MacCallum Cancer Centre. Together we form one of the largest open-access cancer biobanks in Australia.
Our extensive collection of biospecimens has been generously donated by Victorians willing to contribute to cancer research. Explore our interactive data to gain a real-time snapshot into our inventory and understand the broad range of cancer and specimen types available within our archive. Click the 3 dots for more graph options.
The VCB is a critical infrastructure that provides vital resources for researchers to improve cancer outcomes, and we’re proud to support their pioneering work to change and save lives – it’s innovations like these that demonstrate why the Victorian Government’s investment in medical research is so critically important.
Honorary Ben Carroll, Minister for Medical Research
The support provided by the VCB, which included recruitment and provision of high-quality blood samples from donor participants, was instrumental for the foundational biomarker discovery and development work that we undertook at CSIRO, which has been critical for commercial success.
Dr Kim Fung, Principal Research Scientist
The support provided by the VCB, its staff, and its network of hospitals, and in particular the generosity of its sample donors, have all been critical in enabling the great progress that our company has made in developing a new, simple, blood-based diagnostic test for the early detection of colorectal cancer and our other target cancers.”
Dr Trevor Lockett, Technical Director